Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALISHA M MAVIS

Allopathic & Osteopathic Physicians Pediatrics Pediatric Transplant Hepatology

NPI
1053583823
CMS profile
934283
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$172,418.32

126 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ALBIREO PHARMA, INC. $54,096.69 26
Ipsen Biopharmaceuticals, Inc $53,315.64 22
Mirum Pharmaceuticals, Inc. $52,668.11 65
Alexion Pharmaceuticals, Inc. $6,637.88 10
Echosens North America, Inc. $5,700.00 3

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALISHA M MAVIS

NPI 1053583823 · CMS profile ID 934283

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Transplant Hepatology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053583823?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALISHA M MAVIS, NPI 1053583823, CMS profile ID 934283. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053583823?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ALISHA M MAVIS, NPI 1053583823, CMS profile ID 934283. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053583823?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ALISHA M MAVIS, NPI 1053583823, CMS profile ID 934283, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1053583823?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

126 matching records · $172,418.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 126 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–126 of 126.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ALBIREO PHARMA, INC. $142.5203/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526231 CMS
ALBIREO PHARMA, INC. $107.5003/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526237 CMS
ALBIREO PHARMA, INC. $10,411.0003/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526245 CMS
Mirum Pharmaceuticals, Inc. $3,080.0003/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980603 CMS
Mirum Pharmaceuticals, Inc. $145.1403/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980605 CMS
Mirum Pharmaceuticals, Inc. $5.5203/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980609 CMS
Mirum Pharmaceuticals, Inc. $4.0503/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980611 CMS
Mirum Pharmaceuticals, Inc. $8.9303/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980615 CMS
Mirum Pharmaceuticals, Inc. $445.7903/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980617 CMS
Mirum Pharmaceuticals, Inc. $35.0003/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980621 CMS
Mirum Pharmaceuticals, Inc. $48.3803/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980623 CMS
Mirum Pharmaceuticals, Inc. $17.0003/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980625 CMS
Mirum Pharmaceuticals, Inc. $73.0003/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980629 CMS
Mirum Pharmaceuticals, Inc. $299.0003/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980633 CMS
Mirum Pharmaceuticals, Inc. $962.5003/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980661 CMS
ALBIREO PHARMA, INC. $2,596.5003/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526497 CMS
ALBIREO PHARMA, INC. $80.0002/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526251 CMS
ALBIREO PHARMA, INC. $937.8102/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526257 CMS
ALBIREO PHARMA, INC. $726.1802/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526261 CMS
Mirum Pharmaceuticals, Inc. $770.0002/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980655 CMS
ALBIREO PHARMA, INC. $5,193.0002/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056525170 CMS
ALBIREO PHARMA, INC. $7,212.5002/09/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056525823 CMS
Mirum Pharmaceuticals, Inc. $500.0001/31/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022980659 CMS
Echosens North America, Inc. $1,800.0001/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052145513 CMS
Alexion Pharmaceuticals, Inc. $600.0001/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017013723 CMS
ALBIREO PHARMA, INC. $109.4001/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056526481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,819.40 27
PY2020 $4,203.00 6
PY2021 $6,922.08 6
PY2022 $26,629.23 24
PY2023 $172,418.32 126
PY2024 $104,337.98 96
PY2025 $72,106.50 66

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,882.45 10
PY2024 Principal investigator $15,930.00 1
PY2023 Principal investigator $1,265.00 1
PY2022 Principal investigator $26,091.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ALBIREO PHARMA, INC. $668.75 12/24/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478743
Principal investigator 1 ALBIREO PHARMA, INC. $337.50 10/30/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478741
Principal investigator 1 ALBIREO PHARMA, INC. $37.50 10/09/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478737
Principal investigator 1 ALBIREO PHARMA, INC. $5,171.20 10/09/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478739
Principal investigator 1 ALBIREO PHARMA, INC. $37.50 09/11/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478735
Principal investigator 1 ALBIREO PHARMA, INC. $480.00 08/13/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478733
Principal investigator 1 ALBIREO PHARMA, INC. $2,000.00 07/24/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478725
Principal investigator 1 ALBIREO PHARMA, INC. $1,975.00 07/24/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478727
Principal investigator 1 ALBIREO PHARMA, INC. $2,500.00 07/24/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478729
Principal investigator 1 ALBIREO PHARMA, INC. $17,675.00 07/18/2025 Non-covered Recipient Entity
WAKE FOREST OUTPATIENT NEUROLOGY CLINIC
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176478731